Soliris MG denied as duplicate or overlapping therapy by Aetna?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Aetna typically requires
Aetna's specific coverage criteria for soliris mg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Aetna angle on Soliris MG
## Why Aetna Denied Soliris (Eculizumab) as Duplicate Therapy
Aetna may issue a duplicate-therapy denial when it determines that another agent already on your claim or in your prescription history is intended to treat the same condition through the same mechanism. For Soliris (eculizumab), this most often occurs when a complement-inhibitor or a related biologic appears elsewhere in your medication record, or when the reviewer conflates different complement-pathway conditions that Soliris addresses.
This denial is frequently incorrect and is worth appealing, because the indications for Soliris — such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD) — are distinct, and no interchangeable complement inhibitor is necessarily appropriate for all patients or all diagnoses.
## Federal Appeal Framework
- Internal appeal (ERISA §503 / ACA §2719): You have the right to a full-and-fair internal review. Submit your first-level internal appeal as soon as possible; most plans allow 180 days from the denial notice.
- External review: If the internal appeal is denied, you are entitled to an independent external review under ACA §2719. The general window to request external review is approximately four months (180 days) from the final internal denial. Expedited external review — with a decision in as little as 72 hours — is available when a standard timeline would seriously jeopardize your health.
## Appeal Process and Timeline
1. Request the complete denial letter and the plan's clinical criteria used to classify a treatment as a duplicate. 2. File a written internal appeal identifying the specific assertion of duplication and rebutting it point by point. 3. If denied internally, file for external review with your state's insurance commissioner or the federal external-review program.
## Documentation to Gather
- Diagnosis confirmation: ICD-10 diagnosis code(s) on file, with supporting lab and clinical findings confirming the precise indication Soliris is prescribed for.
- Medication history: A complete list of all current and recent medications, annotated to show mechanism and indication — demonstrating no true duplicate exists.
- Prescriber medical-necessity letter: A letter from your treating specialist explaining why Soliris is uniquely necessary, why no other agent on your record treats the same condition through the same pathway, and what clinical harm would result from substitution.
- Chart documentation: Clinical notes, lab trends, and specialist assessments that document disease activity and treatment response history.
## Criteria-Mapping Structure
Obtain Aetna's published coverage policy for Soliris and its definition of "duplicate therapy." For each criterion listed, document the exact chart fact that addresses it. For example: if the policy requires that no other complement inhibitor be active for the same diagnosis, confirm in writing — with dates — that no such agent appears on your active medication list for this indication. Align the FDA-approved prescribing information for Soliris with the insurer's criteria to show that the prescribed use is within the labeled indication and is not replicated by any other covered drug.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →